Agenus Inc.
Clinical trials sponsored by Agenus Inc., explained in plain language.
A biotech developing immunotherapies for cancer.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug combo aims to shrink Hard-to-Treat colorectal tumors Results expected Sep 2027 (estimated) May already have reported ↗
-
Can a Two-Antibody combo outsmart advanced cancer?
Disease control CompletedThis early-stage trial is testing whether combining two experimental immunotherapy drugs, zalifrelimab and balstilimab, can help shrink or control advanced solid tumors, including cervical cancer. The drugs are designed to block different 'brakes' on the immune system, potentiall…
Phase 1/2 • Sponsor: Agenus Inc. • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New immunotherapy combo takes on tough pancreatic cancer
Disease control CompletedThis phase 2 trial tested whether adding an immunotherapy drug called botensilimab to standard chemotherapy could help people with metastatic pancreatic cancer who had already progressed on a common chemo regimen (FOLFIRINOX). The study enrolled 81 participants and compared the c…
Phase 2 • Sponsor: Agenus Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New antibody combo tested in advanced cancer patients
Disease control CompletedThis early-phase trial tested a new antibody drug called AGEN1777, given alone or with another antibody (a PD-1 inhibitor), in 25 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, find the right dose, and se…
Phase 1 • Sponsor: Agenus Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC